RU2019108100A - Композиции никотинамид рибозида и птеростильбена и методы лечения нейродегенеративных заболеваний - Google Patents
Композиции никотинамид рибозида и птеростильбена и методы лечения нейродегенеративных заболеваний Download PDFInfo
- Publication number
- RU2019108100A RU2019108100A RU2019108100A RU2019108100A RU2019108100A RU 2019108100 A RU2019108100 A RU 2019108100A RU 2019108100 A RU2019108100 A RU 2019108100A RU 2019108100 A RU2019108100 A RU 2019108100A RU 2019108100 A RU2019108100 A RU 2019108100A
- Authority
- RU
- Russia
- Prior art keywords
- disease
- composition
- pterostilbene
- neurodegenerative disease
- nicotinamide riboside
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662378053P | 2016-08-22 | 2016-08-22 | |
| US62/378,053 | 2016-08-22 | ||
| PCT/US2017/047979 WO2018039207A1 (en) | 2016-08-22 | 2017-08-22 | Nicotinamide riboside and pterostilbene compositions and methods for treatment of neurodegenerative disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2019108100A true RU2019108100A (ru) | 2020-09-22 |
| RU2019108100A3 RU2019108100A3 (enExample) | 2020-11-27 |
Family
ID=61246253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019108100A RU2019108100A (ru) | 2016-08-22 | 2017-08-22 | Композиции никотинамид рибозида и птеростильбена и методы лечения нейродегенеративных заболеваний |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11260069B2 (enExample) |
| EP (1) | EP3500267A4 (enExample) |
| JP (1) | JP7132907B2 (enExample) |
| KR (1) | KR20190046895A (enExample) |
| CN (2) | CN109982706A (enExample) |
| AU (1) | AU2017316614B2 (enExample) |
| BR (1) | BR112019003579A2 (enExample) |
| CA (1) | CA3034673A1 (enExample) |
| MX (1) | MX2019002211A (enExample) |
| RU (1) | RU2019108100A (enExample) |
| WO (1) | WO2018039207A1 (enExample) |
| ZA (1) | ZA201901536B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7132907B2 (ja) | 2016-08-22 | 2022-09-07 | エリジウム・ヘルス・インコーポレイテッド | ニコチンアミドリボシド及びプテロスチルベン組成物及び神経変性障害の治療方法 |
| EP3624808A4 (en) * | 2017-05-18 | 2021-03-03 | Elysium Health, Inc. | PROCEDURES AND COMPOSITIONS FOR IMPROVED SLEEP |
| US11286274B2 (en) | 2017-06-19 | 2022-03-29 | Mitopower Llc | Nicotinamide riboside derivatives and their uses |
| CA3108015A1 (en) | 2017-07-28 | 2019-01-31 | Centers For Age Control, Inc. | Compositions and methods for preventing and reversing aspects of aging |
| CN112955150A (zh) * | 2018-10-19 | 2021-06-11 | 达萨玛治疗公司 | 与nad+或nad+前体组合的sarm1抑制剂 |
| WO2020102326A1 (en) * | 2018-11-13 | 2020-05-22 | Elysium Health, Inc | Methods for determining and increasing nad levels |
| WO2020131578A2 (en) | 2018-12-17 | 2020-06-25 | Mitopower Llc | Nicotinyl riboside compounds and their uses |
| JP7580380B2 (ja) * | 2019-02-26 | 2024-11-11 | ウニベルシタット デ バレンシア―エストゥディ ジェネラル | 運動ニューロン疾患を処置するための方法及び組成物 |
| CN110812365A (zh) * | 2019-11-07 | 2020-02-21 | 明特奇点医疗科技（北京）有限公司 | 一种组合物及其制备方法与制剂 |
| CN111838669B (zh) * | 2020-08-07 | 2022-11-29 | 四川大学华西医院 | 治疗改善易损脏器的纳米组合物、制剂及制备方法和用途 |
| EP4029496A1 (en) * | 2021-01-18 | 2022-07-20 | Universitat de València | Pterostilbene and silibinin for preventing, ameliorating or reducing radiation-induced diseases |
| EP4079311B1 (en) | 2021-04-20 | 2025-10-01 | Nuvamid SA | Nmn and derivatives for use in the treatment of depression and/or anxiety in patients having a form of parkinsonism |
| WO2022269064A1 (en) * | 2021-06-24 | 2022-12-29 | Vestlandets Innovasjonsselskap As (Vis) | Nad-augmentation therapy for parkinson's disease |
| DK4284387T3 (da) * | 2021-06-24 | 2024-09-02 | Vestlandets Innovasjonsselskap As Vis | Nad-forstærkelsesterapi til parkinsons sygdom |
| CN117615768A (zh) * | 2021-06-24 | 2024-02-27 | 韦斯特兰德特斯创新股份公司 | 用于帕金森病的nad增效疗法 |
| CN118176006A (zh) * | 2021-10-27 | 2024-06-11 | 益力舒健康公司 | 治疗更年期综合征的方法 |
| EP4727544A2 (en) | 2023-06-14 | 2026-04-22 | Chromadex Inc. | Nicotinamide riboside and derivatives thereof in intravenous formulations and methods of use thereof |
| CN116807985A (zh) * | 2023-06-20 | 2023-09-29 | 风火轮(上海)生物科技有限公司 | 一种烟酰胺核糖组合物及其制备方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1964627B (zh) | 2004-06-04 | 2011-10-19 | 华盛顿大学 | 治疗神经病变的方法和组合物 |
| EP2805719A1 (en) | 2005-03-30 | 2014-11-26 | Glaxosmithkline LLC | Nicotinamide riboside and analogues thereof |
| US20090069444A1 (en) | 2007-09-07 | 2009-03-12 | The United States Of America, As Represented By Th E Secretary Of Agriculture | Method to Ameliorate Oxidative Stress and Improve Working Memory Via Pterostilbene Administration |
| US20090163580A1 (en) * | 2007-12-24 | 2009-06-25 | Natrol, Inc. | Anti-aging composition containing resveratrol and method of administration |
| WO2010095926A1 (en) * | 2009-02-20 | 2010-08-26 | N.V. Nutricia | Use of reveratrol for preserving cognitive functioning |
| EP2445488B1 (en) | 2009-06-22 | 2020-03-18 | Indus Biotech Private Limited | Process for obtaining purified pterostilbene and methods of use thereof |
| WO2011011721A2 (en) | 2009-07-24 | 2011-01-27 | Amazentis Sa | Compounds, compositions and methods for protecting brain health in neurodegenerative disorders |
| US9439875B2 (en) | 2011-05-11 | 2016-09-13 | The United States Of America, As Represented By The Secretary Of Agriculture | Anxiolytic effect of pterostilbene |
| EP2574339A1 (de) * | 2011-09-27 | 2013-04-03 | Johannes Huber | Pharmazeutisches Präparat zur Behandlung von NADH-bedingten Erkrankungen |
| US20130149277A1 (en) | 2011-12-13 | 2013-06-13 | Cliffstar Llc | Pterostilbene and pvp grape juice extract combination for treatment of metabolic, vascular, and neurodegenerative disorders |
| US20130296440A1 (en) | 2012-05-01 | 2013-11-07 | ChromaDex Inc. | Pterostilbene and curcumin combination for treatment of oxidative stress and inflammation |
| JP6509844B2 (ja) * | 2013-10-30 | 2019-05-08 | クロマデックス, インコーポレイテッドChromaDex, Inc. | 皮膚症状の治療において局所使用されるニコチンアミドリボシド組成物 |
| US10316054B2 (en) | 2014-06-02 | 2019-06-11 | Glaxosmithkline Intellectual Property (No. 2) Limited | Preparation and use of crystalline beta-D-nicotinamide riboside |
| WO2016122832A1 (en) * | 2015-01-30 | 2016-08-04 | Natural Formulations | Compositions, therapeutic and prophylactic methods for treatment of neurodegenerative diseases and brain injuries |
| WO2016149277A1 (en) * | 2015-03-17 | 2016-09-22 | Specialty Nutrition Group, Inc. | Nutritional compositions to enhance mitochondrial energy production |
| JP7132907B2 (ja) | 2016-08-22 | 2022-09-07 | エリジウム・ヘルス・インコーポレイテッド | ニコチンアミドリボシド及びプテロスチルベン組成物及び神経変性障害の治療方法 |
-
2017
- 2017-08-22 JP JP2019510843A patent/JP7132907B2/ja active Active
- 2017-08-22 MX MX2019002211A patent/MX2019002211A/es unknown
- 2017-08-22 BR BR112019003579-6A patent/BR112019003579A2/pt not_active Application Discontinuation
- 2017-08-22 CN CN201780064669.9A patent/CN109982706A/zh active Pending
- 2017-08-22 US US16/327,651 patent/US11260069B2/en active Active
- 2017-08-22 CN CN202211250881.3A patent/CN115645432A/zh active Pending
- 2017-08-22 RU RU2019108100A patent/RU2019108100A/ru not_active Application Discontinuation
- 2017-08-22 WO PCT/US2017/047979 patent/WO2018039207A1/en not_active Ceased
- 2017-08-22 CA CA3034673A patent/CA3034673A1/en active Pending
- 2017-08-22 EP EP17844270.3A patent/EP3500267A4/en not_active Withdrawn
- 2017-08-22 KR KR1020197008293A patent/KR20190046895A/ko not_active Ceased
- 2017-08-22 AU AU2017316614A patent/AU2017316614B2/en active Active
-
2019
- 2019-03-12 ZA ZA2019/01536A patent/ZA201901536B/en unknown
-
2022
- 2022-01-21 US US17/580,999 patent/US11998561B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017316614A1 (en) | 2019-03-21 |
| EP3500267A4 (en) | 2020-03-18 |
| CN109982706A (zh) | 2019-07-05 |
| MX2019002211A (es) | 2019-10-30 |
| RU2019108100A3 (enExample) | 2020-11-27 |
| US20220143055A1 (en) | 2022-05-12 |
| BR112019003579A2 (pt) | 2019-05-21 |
| US11998561B2 (en) | 2024-06-04 |
| US11260069B2 (en) | 2022-03-01 |
| US20190201426A1 (en) | 2019-07-04 |
| ZA201901536B (en) | 2024-06-26 |
| JP7132907B2 (ja) | 2022-09-07 |
| EP3500267A1 (en) | 2019-06-26 |
| JP2019524856A (ja) | 2019-09-05 |
| CN115645432A (zh) | 2023-01-31 |
| WO2018039207A1 (en) | 2018-03-01 |
| CA3034673A1 (en) | 2018-03-01 |
| AU2017316614B2 (en) | 2023-06-15 |
| KR20190046895A (ko) | 2019-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019524856A5 (enExample) | ||
| DiMascio et al. | A controlled trial of amantadine in drug-induced extrapyramidal disorders | |
| EP2167066B1 (en) | Droxidopa and pharmaceutical composition thereof for the treatment of attention deficit disorders | |
| CN115884761A (zh) | 大麻素的透皮药物制剂 | |
| RU2005104418A (ru) | Фармацевтические композиции для лечения неврологических расстройств, содержащие декстрометорфан и квинидин | |
| RU2009148288A (ru) | Профилактическое или терапевтическое средство для возрастной дегенерации желтого пятна | |
| JP2018533622A5 (enExample) | ||
| KR20150002640A (ko) | 파킨슨병을 치료하기 위한 신규의 치료적 접근법 | |
| AU2002340971B2 (en) | Use of 2-oxo-1-pyrrolidine derivatives for the treatment of dyskinesia and movement disorders | |
| US5837701A (en) | Composition and method for treating conditions associated with symptoms of unspecified retarded maturation | |
| KR20070011276A (ko) | 쿠에티아핀 항정신병제를 사용한 정신병의 치료 | |
| WO2005105120A2 (en) | Pharmaceutical combination, active on central nervous system (cns) and set of pharmaceuticals; method of treatment of cns-disorders; means facilitating penetration of the hematoencephalic barrier; pharmaceutical means for endonasal administration | |
| MY205498A (en) | Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye | |
| JPWO2008099781A1 (ja) | アミノアルコール誘導体を有効成分とする脱髄性疾患の治療剤又は予防剤 | |
| CA3033050C (en) | Triple combination of histamine-3 receptor inverse agonists, acetylcholinesterase inhibitors and nmda receptor antagonist | |
| RU2469734C2 (ru) | Лечебное средство для лечения расстройств аккомодаций "stiak" | |
| Zier et al. | Procyclidine hydrochloride (Kemadrin) treatment of parkinsonism: Result in 108 patients | |
| CN118159267A (zh) | 用于治疗神经退行性眼病的普利多匹定及其类似物 | |
| CA3201259A1 (en) | Masitinib for the treatment of alzheimer's disease | |
| Bhatt et al. | Parkinson's disease | |
| Gupta et al. | Levosulpiride: A review | |
| CN109640975B (zh) | 组胺-3受体反向激动剂与乙酰胆碱酯酶抑制剂的组合 | |
| CN1290166A (zh) | 运动障碍的治疗 | |
| JP3494651B2 (ja) | 神経変性疾患の治療を目的とする医薬生成物の製造のためのエファロキサンおよびその誘導体の使用 | |
| CN1309563B (zh) | 1-(氨基烷基)-3-喹喔啉-2-酮类衍生物在制备具有抗氧化剂作用的组合物中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20210331 |